Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Opening Session Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Jul
18
Today In Oncology
COVID-19 Boosters Offer Protection for Patients With Cancer
Can Use of Aprepitant During Chemotherapy Improve Triple-Negative Breast Cancer Outcomes
Urothelial Cancer Survival in the Eras Before and After Immune Checkpoint Inhibitors and Antibody-Drug Conjugates
Early ctDNA Change and Outcomes With ICI Treatment in Metastatic Colorectal Cancer
Classifying Pancreatic Cysts Using AI Models
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo